Skip to content
10-K

Annual Report

Aurinia Pharmaceuticals Inc. AUPH

0001600620-25-000011

← back to feed
Filed
Feb 27, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 25, 2025 137.34M sh
Current Liabilities FY 2024 · Dec 31, 2023 $77.19M
Total Liabilities FY 2024 · Dec 31, 2023 $170.11M
Current Assets FY 2024 · Dec 31, 2023 $424.8M
Total Assets FY 2024 · Dec 31, 2023 $548.06M
Eps Diluted FY 2024 · Dec 31, 2023 −$0.19
Eps Diluted FY 2024 · Sep 30, 2023 −$0.09
Eps Diluted FY 2024 · Jun 30, 2023 −$0.08
Eps Diluted FY 2024 · Mar 31, 2023 −$0.18
Eps Diluted FY 2024 · Dec 31, 2022 −$0.76
Eps Basic FY 2024 · Dec 31, 2023 −$0.19
Eps Basic FY 2024 · Sep 30, 2023 −$0.09
Eps Basic FY 2024 · Jun 30, 2023 −$0.08
Eps Basic FY 2024 · Mar 31, 2023 −$0.18
Eps Basic FY 2024 · Dec 31, 2022 −$0.76
Net Income FY 2024 · Dec 31, 2023 −$26.88M
Net Income FY 2024 · Sep 30, 2023 −$13.45M
Net Income FY 2024 · Jun 30, 2023 −$11.49M
Net Income FY 2024 · Mar 31, 2023 −$26.21M
Net Income FY 2024 · Dec 31, 2022 −$108.18M
Operating Income FY 2024 · Dec 31, 2023 −$29.67M
Operating Income FY 2024 · Sep 30, 2023 −$16.26M
Operating Income FY 2024 · Jun 30, 2023 −$16.17M
Operating Income FY 2024 · Mar 31, 2023 −$29.58M
Operating Income FY 2024 · Dec 31, 2022 −$111.47M
Revenue FY 2024 · Dec 31, 2023 $45.1M
Revenue FY 2024 · Sep 30, 2023 $54.52M
Revenue FY 2024 · Jun 30, 2023 $41.49M
Revenue FY 2024 · Mar 31, 2023 $34.41M
Revenue FY 2024 · Dec 31, 2022 $134.03M
Shares Diluted FY 2024 · Dec 31, 2022 141.92M sh
Stock Repurchased FY 2024 · Dec 31, 2022 $0
Operating Cash Flow FY 2024 · Dec 31, 2022 −$79.53M
Cash And Equivalents FY 2024 · Dec 31, 2022 $94.09M
Rd Expense FY 2024 · Dec 31, 2022 $44.99M
Cost Of Revenue FY 2024 · Dec 31, 2022 $5.66M
Stockholders Equity FY 2024 · Dec 31, 2021 $479.09M